Tuesday, October 20, 2026, 11 AM-12 PM ET
Hear experts review the biological and clinical significance of the HER2 expression continuum in breast tissue, providing a clearer understanding of how these variations might impact diagnosis, and discuss the emerging importance of documenting HER2-low and HER2-ultralow categories using a validated IHC assay.
Webinar presenters Keith Wharton, MD, PhD, Global Medical Affairs Leader–Pathology, Roche Diagnostics Solutions, and Hannah Y. Wen, MD, PhD, Director, Breast Pathology Fellowship, Associate Team Leader, Breast Pathology Team, Attending Pathologist, Memorial Sloan Kettering Cancer Center
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Roche.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Thursday, October 29, 2026, 1 PM-2 PM ET
Hear an expert discuss the evolving role of PD-L1 testing in HNSCC and ovarian cancer.
Webinar presenter Georgios Deftereos, MD, Professor of Pathology, Associate Director of the Clinical Cancer Genomics Laboratory, Director of Molecular Cytopathology, University of California, San Francisco
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Agilent.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Tuesday, November 3, 2026, 1 PM-2 PM ET
Hear an expert discuss the challenges of detecting NRG1 fusions and how RNA-based testing can support more comprehensive fusion identification in clinical practice.
Webinar presenter Benjamin Weinberg, MD, Associate Professor of Medicine and Attending Physician
specializing in gastrointestinal medical oncology
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Diaceutics.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Tuesday, November 10, 2026, 1 PM-2 PM ET
Join us for a session to help improve diagnostic accuracy in your practice when scoring HER2 IHC 0 with faint, incomplete membrane staining in ≤10% of tumor cells vs IHC 0 with no membrane staining detected in patients with mBC.
Webinar presenter Jeffrey Gregg, MD, University of Nevada
CAP TODAY does not endorse any of the products or services named within. This program is being sponsored by Daiichi Sankyo, Inc. and AstraZeneca. The speaker is being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Monday, November 16, 2026, 12:30 PM-2 PM ET
Hear experts discuss a multidisciplinary approach to oncopathology for HER2
assessments for solid tumors in the absence of a companion diagnostic.
Webinar presenters Funda Meric-Bernstam, MD, Chair, Department of Investigational Cancer Therapeutics Medical Director, Institute for Personalized Cancer Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas, and Emina E. Torlakovic, MD, PhD, College of Medicine, University of Saskatchewan, Canadian Biomarker Quality Assurance, Saskatoon, Saskatchewan, Canada, and Carol Cheung, MD, PhD, JD, FRCPC, Deputy Director, Canadian Biomarker Quality, Assurance—Programme canadien d’assurance de la qualité des biomarqueurs
CAP TODAY does not endorse any of the products or services named within. This program is being sponsored by Daiichi Sankyo, Inc. and AstraZeneca. The speaker is being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
SciGene’s new sodium thiocyanate pretreatment reagent, a convenient 1-M liquid formulation of NaSCN for pretreating tissue samples prior to application of nucleic acid probes for cytogenetic assays, joins an expanding line of FISH slide-processing products from SciGene.
Smart Imaging Technologies’ Interactive Web Reports for its Simagis Live Digital Pathology servers make it possible for pathologists to complete and sign off digital cases, create professional, media-rich reports from digital slides, and share them instantly with clients, colleagues, or patients.
The Clinical and Laboratory Standards Institute has published an updated version of “MM07-A2–Fluorescence In Situ Hybridization Methods for Clinical Laboratories; Approved Guideline–Second Edition.” This document addresses FISH methods for medical genetic determinations, identification of chromosomal abnormalities, and gene amplification.
Waters Corp. has unveiled its Web-based Oasis method development tools, which are designed to help customers reduce their sample preparation method development time as part of Waters’ simple prep campaign.
Denville Scientific’s new line of microscopes includes basic and advanced models designed to provide maximum optical performance on durable and affordable platforms.
The selection includes epifluorescence and stereo-zoom models as well as models with trinocular camera and video mounts. A range of objectives are available, and all microscopes come with a five-year mechanical warranty.
The Liquidator 96 bench-scale manual pipetting solution from Mettler Toledo subsidiary Rainin Instrument provides accuracy without forcing operators to contend with electronic systems or complex computer programming.
Luminex announced it has received FDA and European clearance for a comprehensive genotyping assay, xTAG CYP2C19 kit. This new test provides a personalized approach to determining patient treatment based on certain genetic variants of the P450 2C19 gene.
Multisorb Technologies offers its Quality by Design (QbD)-based Calculations through Operations Program. Multisorb’s scientists use the program to determine the optimized sorbent for the application and to manage placement of that sorbent during packaging operations, when required, with the use of a sorbent-specific dispenser. The program and use of a Multisorb system provide an effective solution for ensuring chemical and physical stability for IVD devices through their desired shelf life. For complex stability requirements, optimized sorbent solutions are available with
SISCAPA Assay Technologies (SAT) announced publication of a study in Clinical Chemistry demonstrating that one of the company’s MALDI-TOF assays for protein C inhibitor can help identify patients at risk for recurrence of prostate cancer after radiotherapy. The assay measures a proteotypic peptide of protein C inhibitor enriched from tryptic digests of patient serum by anti-peptide antibodies (the SISCAPA, or Stable Isotope Standards and Capture by Anti-Peptide Antibodies, workflow), followed by quantitation using simple MALDI-TOF mass spectrometry. A significant post-treatment
Sagentia has completed initial alpha prototype development of the Resolution microbial genotyping system that it is developing for PathoGenetix. Sagentia has worked with PathoGenetix for the past two years across the full product development life cycle, helping to combine two bread board systems into an intuitive, usable system with a smaller footprint. The Resolution system is based on PathoGenetix’s Genome Sequence Scanning (GSS) technology developed to detect biothreat pathogens in environmental samples. The technology is being developed for faster and
